Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody
about
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelopeInduction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodiesDifferential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains.Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures.
P2860
Q33426352-CFF3DD4D-F113-42F0-8B9E-1AE9DD63323BQ33839402-34D0598A-D024-48AF-ABDA-E6CA2C919B63Q33842286-7D799004-FA45-4381-A26F-D6C0CF61397CQ34142795-3A25F711-D014-4593-B227-B9AB85A0DDBDQ34359035-1FED14FD-013B-46A7-A7CD-9AD945E4493FQ34681455-C9500701-64E3-40C3-90E4-FB135FA6B578Q34970873-09C92DB7-8256-4F5B-8772-565512DE7542Q35880498-7AA1B5F6-591F-4E5F-875F-58278D2F1334Q35898116-A35C6440-3145-4468-A543-8332E22CEE08Q36491733-0BF60BC9-B80C-41E8-AAC5-3D8759D93395Q39878965-601C50D4-C69A-412F-A227-D0032D3721C2Q42797346-35BB4FE7-0ABF-46FB-B44A-C814328836F6
P2860
Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Mechanisms of human immunodefi ...... ctivity by anti-HIV-1 antibody
@ast
Mechanisms of human immunodefi ...... ctivity by anti-HIV-1 antibody
@en
type
label
Mechanisms of human immunodefi ...... ctivity by anti-HIV-1 antibody
@ast
Mechanisms of human immunodefi ...... ctivity by anti-HIV-1 antibody
@en
prefLabel
Mechanisms of human immunodefi ...... ctivity by anti-HIV-1 antibody
@ast
Mechanisms of human immunodefi ...... ctivity by anti-HIV-1 antibody
@en
P2093
P2860
P1433
P1476
Mechanisms of human immunodefi ...... ctivity by anti-HIV-1 antibody
@en
P2093
Kennedy MS
McDougal JS
Nicholson JK
P2860
P304
P407
P577
1996-08-01T00:00:00Z